Reclassification of Genetic Variants in Patients with Hypertrophic Cardiomyopathy from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
- 1Garvan Institute of Medical Research, and UNSW Sydney, Sydney, NSW, Australia
Abstract
BackgroundGenetic testing is a Class I recommendation for patients with hypertrophic cardiomyopathy (HCM). Variant classification relies on evidence from publicly available case data, evolving classification rules, and gene-disease associations. Thus, as knowledge increases, genetic variant classifications change over time. We evaluated the occurrence and reasons for variant reclassification from a large multi-center international HCM registry (Sarcomeric Human Cardiomyopathy Registry; SHaRe), with the goal to minimize uncertainty for patients and clinicians.
MethodsParticipants receive clinical care at specialized HCM centres. Baseline classifications were derived from the clinical genetic test report (original or updated) or prior further adjudication by SHaRe geneticists. All variants were then computationally reannotated and reevaluated during 2024-2025. Variants underwent expedited curation if no new evidence was present. The remainder underwent full manual curation using accepted criteria and classified as pathogenic/likely pathogenic (P/LP), variant of uncertain significance (VUS) and benign/likely benign (B/LB). VUS were sub-classified to high, mid or low.
ResultsOf 12,187 HCM patients, 8,054 (66%) had genetic testing between 1990-2024, and 4,923 (61%) had a variant identified in one of 29 ClinGen-validated HCM genes (1606 unique variants). Expedited curation was performed for 704 (44%) variants and 902 (56%) underwent manual curation. There were 1279 (79%) variants that retained their classification: 148 B/LB, 663 VUS, and 468 P/LP. While 276 (17%) variants (n=557 patients) were reclassified, including 73 upgrades: 61 from VUS to P/LP (199 patients), and 12 from B/LB to VUS. There were 203 downgrades: 108 from P/LP to VUS (196 patients), and 95 from P/LP or VUS to B/LB. VUS were additionally subclassified: 90 VUS-High, 129 VUS-Mid, 115 VUS-Low. Sub-classification of VUS resulted in less uncertainty, with 369 (40.6%) variants reclassified as VUS-Low or B/LB, indicating a very strong probability of not being HCM associated.
ConclusionsClinically meaningful reclassification occurred in 10% of variants identified in HCM probands. Most VUS were unlikely to be causal, and sub-classification has potential to reduce their burden on clinicians and families. Contemporary approaches to classification can minimize uncertainty of genetic results and highlight the need for periodic reevaluation.
Related
- Predictive Value of P-Wave Dispersion Combined with Left Atrial Reservoir Strain for Incident Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Retrospective Cohort Study.
- Physical activity and quality of life in patients with hypertrophic cardiomyopathy in Japan: a quantitative study
- Clinical effectiveness of mavacamten on cardiac function and disease-related indicators in patients with obstructive hypertrophic cardiomyopathy
- Left Ventricular Diastolic Intraventricular Pressure Differences and Propagation Velocity with 4D-Flow MRI in Patients with Hypertrophic Cardiomyopathy
- A late bloom at the apex: development of apical hypertrophic cardiomyopathy phenotype in advanced age
BibTeX
@misc{hespe2026reclassification,
title = {{Reclassification of Genetic Variants in Patients with Hypertrophic Cardiomyopathy from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)}},
author = {S. Hespe and G. Powell and L. Catto and N. Stewart and A. Baker and N. Krishnan and L. A. Mitchell and N. Henden and E. Richardson and A. Butters and P. Theotokis and R. Buchan and K. A. McGurk and B. Claggett and D. Abrams and E. Ashley and V. N. Parikh and S. M. Day and A. S. Helms and R. Lampert and K. Y. Lin and J. W. Rossano and P. P. Zwetsloot and M. Michels and E. M. Miller and F. Girolami and I. Olivotto and A. Owens and A. C. Pereira and T. D. Ryan and S. Saberi and M. W. Russell and J. C. Stendahl and B. Gray and A. Argiro and N. Maurizi and L. Crotti and C. R. Vissing and N. K. Lakdawala and C. Y. Ho and J. S. Ware and J. Ingles},
howpublished = {medRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.05.26359735},
url = {https://www.medrxiv.org/content/10.64898/2026.08.05.26359735v2},
note = {CC BY},
}
RIS
TY - UNPB
TI - Reclassification of Genetic Variants in Patients with Hypertrophic Cardiomyopathy from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
AU - S. Hespe
AU - G. Powell
AU - L. Catto
AU - N. Stewart
AU - A. Baker
AU - N. Krishnan
AU - L. A. Mitchell
AU - N. Henden
AU - E. Richardson
AU - A. Butters
AU - P. Theotokis
AU - R. Buchan
AU - K. A. McGurk
AU - B. Claggett
AU - D. Abrams
AU - E. Ashley
AU - V. N. Parikh
AU - S. M. Day
AU - A. S. Helms
AU - R. Lampert
AU - K. Y. Lin
AU - J. W. Rossano
AU - P. P. Zwetsloot
AU - M. Michels
AU - E. M. Miller
AU - F. Girolami
AU - I. Olivotto
AU - A. Owens
AU - A. C. Pereira
AU - T. D. Ryan
AU - S. Saberi
AU - M. W. Russell
AU - J. C. Stendahl
AU - B. Gray
AU - A. Argiro
AU - N. Maurizi
AU - L. Crotti
AU - C. R. Vissing
AU - N. K. Lakdawala
AU - C. Y. Ho
AU - J. S. Ware
AU - J. Ingles
PY - 2026
DA - 2026/08/05
PB - medRxiv
DO - 10.64898/2026.08.05.26359735
UR - https://www.medrxiv.org/content/10.64898/2026.08.05.26359735v2
AB - BackgroundGenetic testing is a Class I recommendation for patients with hypertrophic cardiomyopathy (HCM). Variant classification relies on evidence from publicly available case data, evolving classification rules, and gene-disease associations. Thus, as knowledge increases, genetic variant classifications change over time. We evaluated the occurrence and reasons for variant reclassification from a large multi-center international HCM registry (Sarcomeric Human Cardiomyopathy Registry; SHaRe), with the goal to minimize uncertainty for patients and clinicians. MethodsParticipants receive clinical care at specialized HCM centres. Baseline classifications were derived from the clinical genetic test report (original or updated) or prior further adjudication by SHaRe geneticists. All variants were then computationally reannotated and reevaluated during 2024-2025. Variants underwent expedited curation if no new evidence was present. The remainder underwent full manual curation using accepted criteria and classified as pathogenic/likely pathogenic (P/LP), variant of uncertain significance (VUS) and benign/likely benign (B/LB). VUS were sub-classified to high, mid or low. ResultsOf 12,187 HCM patients, 8,054 (66%) had genetic testing between 1990-2024, and 4,923 (61%) had a variant identified in one of 29 ClinGen-validated HCM genes (1606 unique variants). Expedited curation was performed for 704 (44%) variants and 902 (56%) underwent manual curation. There were 1279 (79%) variants that retained their classification: 148 B/LB, 663 VUS, and 468 P/LP. While 276 (17%) variants (n=557 patients) were reclassified, including 73 upgrades: 61 from VUS to P/LP (199 patients), and 12 from B/LB to VUS. There were 203 downgrades: 108 from P/LP to VUS (196 patients), and 95 from P/LP or VUS to B/LB. VUS were additionally subclassified: 90 VUS-High, 129 VUS-Mid, 115 VUS-Low. Sub-classification of VUS resulted in less uncertainty, with 369 (40.6%) variants reclassified as VUS-Low or B/LB, indicating a very strong probability of not being HCM associated. ConclusionsClinically meaningful reclassification occurred in 10% of variants identified in HCM probands. Most VUS were unlikely to be causal, and sub-classification has potential to reduce their burden on clinicians and families. Contemporary approaches to classification can minimize uncertainty of genetic results and highlight the need for periodic reevaluation.
ER -